Pfizer is moving its monthly-dosed GLP-1 injection PF-3944 — now named berobenatide — into ten-plus phase 3 studies in 2026, after phase 2b data showed up to 12.3% placebo-adjusted weight loss at 28 weeks with one shot every four weeks. Pfizer presented the full data at the American Diabetes Association meeting in June 2026 (see the update below). It stacks up as the first realistically once-monthly weight-loss injection — competitive on efficacy with weekly semaglutide and a fraction of the dosing burden.
Research-context information only. Peptides and investigational drugs discussed below are research compounds. Protocols, doses, and reactions reported come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
This is the molecule Pfizer paid $10 billion for when it bought Metsera in November 2025 in a contentious bidding war with Novo Nordisk. The phase 2b readout is the first major weight-loss data Pfizer has owned since the acquisition closed, and it is the first credible sign that monthly GLP-1 dosing is mechanically and clinically viable — not just a marketing aspiration.
Update 2026-06-12: ADA Data Is Out — and PF-3944 Now Has a Name
The detailed readout landed at the American Diabetes Association Scientific Sessions (June 5-8, New Orleans), and the molecule now carries its official generic name: berobenatide (development codes PF-3944 / PF-08653944 / MET-097i — all the same compound). Pfizer presented the full VESPER program in a late-breaking symposium, expanding well beyond the single VESPER-3 readout this article was originally built around.
What the ADA data added:
- VESPER-1 extension (obesity, no diabetes): 15.9% mean weight loss at 32 weeks on the 2.4 mg weekly dose — reported with no weight-loss plateau at the 32-week timepoint, meaning the curve was still descending.
- VESPER-2 (obesity/overweight + type 2 diabetes): dose-dependent weight loss plus a 2.2% HbA1c reduction at the 1.6 mg weekly dose versus 0.2% on placebo — confirming the molecule works in the diabetes population, not just non-diabetic obesity.
- VESPER-3 (the monthly-dosing trial detailed below): confirmed 12.3% placebo-adjusted weight loss at week 28 on the 4.8 mg monthly arm, with the GI tolerability breakdown filled in. Severe nausea or vomiting occurred no more than once per dose group, severe diarrhea zero times, and discontinuations were balanced (five during the weekly phase, five during the monthly phase) across the two highest-dose arms.
The headline tension analysts flagged: the 15.9% VESPER-1 figure is total (non-placebo-adjusted) at a weekly dose, while the marquee monthly number is 12.3% placebo-adjusted. The monthly cadence — berobenatide's entire commercial pitch — comes with a modest efficacy trade versus the weekly version, which puts it ahead of weekly semaglutide on convenience but behind weekly tirzepatide (20.9% at 72 weeks) on raw weight loss. BMO Capital Markets called the data "competitive," noting Pfizer's plan to pair berobenatide with its amylin asset MET-233i. Pfizer is advancing the phase 3 VESPER program — VESPER-4 (weekly, obesity), VESPER-5 (diabetes, testing the higher 2.4 mg dose), and VESPER-6 (the monthly maintenance evaluation) — as part of 10+ planned phase 3 studies in 2026. Nothing about availability changed: berobenatide remains years from any FDA filing, and it will never appear in a compounding pharmacy or research-peptide catalog.
What PF-3944 Actually Is
PF-3944 is an ultra-long-acting, fully-biased injectable GLP-1 receptor agonist. The two design features matter:
Ultra-long-acting means the molecule's pharmacokinetic half-life supports a four-week dosing interval. Weekly GLP-1s like semaglutide and tirzepatide have half-lives of roughly 5-7 days; PF-3944's effective half-life is engineered for once-monthly subcutaneous administration without losing therapeutic plasma concentration between doses.
Fully-biased means the molecule preferentially activates the cAMP pathway downstream of GLP-1 receptor binding while reducing beta-arrestin pathway activation. Beta-arrestin signaling is associated with receptor desensitization and some of the GI tolerability problems seen with conventional GLP-1s. Metsera's pre-acquisition data argued that this biased agonism produces "class-leading tolerability" — meaning lower nausea, vomiting, and diarrhea rates at matched efficacy.
Whether biased agonism actually delivers tolerability gains in phase 3 is one of the open questions for the program. The phase 2b topline did not include a head-to-head comparison against semaglutide or tirzepatide, so the tolerability claim is still based on cross-trial comparisons.
The VESPER-3 Phase 2b Numbers
Pfizer announced topline results from VESPER-3 on February 2, 2026. The study tested four PF-3944 dose regimens against placebo in adults with obesity or overweight without type 2 diabetes, with the primary endpoint at 28 weeks.
| Dose | Placebo-adjusted weight loss (Week 28) |
|---|---|
| 1.6 mg low | ~7% |
| 3.2 mg low-mid | ~10% |
| 4.8 mg mid | 12.3% |
| Switch (weekly to monthly) | Maintained efficacy |
| 9.6 mg high (modeled, planned for phase 3) | ~16% |
The two structural results worth noting: the switch arm showed PF-3944 can maintain weight loss when patients move from weekly to monthly dosing four-fold less often, and all four active arms beat placebo with statistical significance. The 9.6 mg cohort was not in VESPER-3 — Pfizer is adding it to phase 3 based on dose-response modeling.
For context, weekly semaglutide produced ~15% placebo-adjusted weight loss at 68 weeks in STEP 1, and weekly tirzepatide produced ~21% at 72 weeks in SURMOUNT-1. PF-3944 at 28 weeks is in the same general neighborhood as semaglutide and below tirzepatide, but with one-quarter the injection frequency.
Why Monthly Dosing Actually Matters
The straight efficacy comparison undersells the design pitch. Monthly dosing changes the patient experience in three concrete ways:
Adherence. Real-world GLP-1 adherence is bad. About 40-60% of patients who start weekly injectable semaglutide or tirzepatide stop within a year, often citing injection frequency as a contributor. Once-monthly dosing collapses 52 injection events per year into 12. If the discontinuation rate drops even modestly, the population-level weight-loss math improves — a 12% drug with 80% adherence often beats a 15% drug with 50% adherence.
Tolerability ramp. The titration period — slowly escalating dose to reduce GI side effects — is responsible for most early dropout. A monthly injection interval gives the body more time between exposures and may smooth side-effect peaks. This is the rationale Pfizer's biased-agonism design is meant to amplify.
Travel and access. Monthly refills mean fewer pharmacy interactions, fewer cold-chain shipments for direct-to-patient programs, and fewer scheduled prescribing appointments. The supply-chain and logistics savings flow directly to manufacturer margin and could support more aggressive cash-pay pricing at launch.
The trade-off: if a patient develops severe side effects on day three of a monthly cycle, they have 25 more days of drug exposure. Acute tolerability problems are harder to manage when you cannot just skip the next weekly dose. Phase 3 will need to characterize how often this matters in practice.
How This Reshapes the GLP-1 Landscape
Three things change if PF-3944 hits its phase 3 endpoints:
Pricing pressure on weekly drugs. Pfizer enters a market where weekly semaglutide and tirzepatide already face cash-pay competition from compounded versions at $80-$350 a month. A monthly-dosed branded option needs to price at parity or below the all-in monthly cost of weekly compounded — which puts a real ceiling on how much premium Pfizer can charge for the convenience.
A second-line option for compounded-peptide users. Patients currently using weekly compounded semaglutide at $80-$180 a month or weekly compounded tirzepatide at $150-$350 a month will eventually have a once-monthly branded alternative. The decision tree becomes: stay on weekly compounded for cost, or move to monthly branded for convenience.
Pressure on the oral-pill category. Oral GLP-1s like the oral semaglutide pill and orforglipron pitch convenience as their main differentiator versus weekly injection. A monthly injection erodes that pitch — once-monthly is more convenient than daily oral for most patients, and the efficacy gap between oral pills (~12% weight loss) and monthly PF-3944 (~12-16% modeled) closes the case.
